Literature DB >> 6091806

Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers.

A E Till, H J Gomez, M Hichens, J A Bolognese, W R McNabb, B A Brooks, F Noormohamed, A F Lant.   

Abstract

Enalapril, the ethyl ester of a potent angiotensin converting enzyme inhibitor, enalaprilat, was administered to healthy volunteers as a capsule containing 10 mg of the maleate salt, every 24h for eight doses. Serum profiles show little accumulation of enalaprilat following eight daily doses of enalapril maleate. An average effective half-life for accumulation of approximately 11h was calculated from urine data. Comparison of observed 24-h urinary recoveries of enalaprilat to predicted steady-state recovery indicates that an 'average' steady state for enalaprilat is attained by the third or fourth dose of enalapril maleate. Statistical comparison of daily urinary recoveries, as well as Cmin values for enalaprilat, confirm this. Observed fluctuations in serum and urine data during apparent steady state suggest some day-to-day variability in the absorption of enalapril maleate and/or its hydrolysis to enalaprilat. An accumulation ratio of 1.3 for enalaprilat was calculated from the predicted steady-state urinary recovery and observed urinary recovery for dose one.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091806     DOI: 10.1002/bdd.2510050309

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  31 in total

1.  A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine.

Authors:  E Snoeck; P Jacqmin; A Van Peer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

2.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

3.  Blood pressure response to conventional and low-dose enalapril in chronic renal failure.

Authors:  Thomas Elung-Jensen; Jens Heisterberg; Anne-Lise Kamper; Jesper Sonne; Svend Strandgaard
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

4.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 5.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

6.  Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.

Authors:  Sandeep Dutta; Ronald C Reed
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

7.  Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding.

Authors:  K R Lees; A W Kelman; J L Reid; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

Review 8.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

9.  Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.

Authors:  E G Bevan; G T McInnes; J C Aldigier; J J Conte; J P Grunfeld; S J Harper; B H Meyer; N Pauly; R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

10.  Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment.

Authors:  M Neubeck; D Fliser; M Pritsch; K Weisser; M Fliser; J Nussberger; E Ritz; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.